IBM Watson Uses AI to Determine Patients Who Need Contrast
By MedImaging International staff writers Posted on 10 Oct 2017 |
Image: Researchers at UCSF are utilizing IBM Watson and AI to help determine patients in need of MRI contrast for scans (Photo courtesy of IBM).
Researchers at the University of California, San Francisco (UCSF) have discovered that IBM Watson can help optimize the process of determining which patients need contrast for musculoskeletal MRI scans.
According to a September 18 paper in the Journal of Digital Imaging, the UCSF research team used IBM Watson’s language processing capacity to create an algorithm, which would automatically assign intravenous contrast for musculoskeletal MRI protocols. The aim was to develop and validate a machine learning-based natural language classifier capable of automatically assigning the use of intravenous contrast for musculoskeletal MRI protocols, based upon the study’s free-text clinical indication, thus improving efficiency of the protocoling radiologist and potentially reducing errors.
The researchers then compared the accuracy of IBM Watson, traditional computers, and a radiologist for determining which patients should receive contrast for musculoskeletal MRI scans based upon clinical indications. They found that Watson achieved an overall accuracy of 83.2% as compared to the original radiologist. In addition to its high accuracy in assigning MRI contrast, IBM Watson also offers the advantage of functioning without preprocessing, with the operator requiring only a minimal understanding of machine-learning fundamentals, according to the researchers.
The researchers concluded that the implementation of this automated MRI contrast determination system as a clinical decision support tool can save significant time and effort for the radiologist while potentially reducing error rates, and does not require any change in order entry or workflow.
According to a September 18 paper in the Journal of Digital Imaging, the UCSF research team used IBM Watson’s language processing capacity to create an algorithm, which would automatically assign intravenous contrast for musculoskeletal MRI protocols. The aim was to develop and validate a machine learning-based natural language classifier capable of automatically assigning the use of intravenous contrast for musculoskeletal MRI protocols, based upon the study’s free-text clinical indication, thus improving efficiency of the protocoling radiologist and potentially reducing errors.
The researchers then compared the accuracy of IBM Watson, traditional computers, and a radiologist for determining which patients should receive contrast for musculoskeletal MRI scans based upon clinical indications. They found that Watson achieved an overall accuracy of 83.2% as compared to the original radiologist. In addition to its high accuracy in assigning MRI contrast, IBM Watson also offers the advantage of functioning without preprocessing, with the operator requiring only a minimal understanding of machine-learning fundamentals, according to the researchers.
The researchers concluded that the implementation of this automated MRI contrast determination system as a clinical decision support tool can save significant time and effort for the radiologist while potentially reducing error rates, and does not require any change in order entry or workflow.
Latest Industry News News
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures